Cefiderocol is Noninferior, But not “Game-Changer,” for Gram-negative Bloodstream Infections

Cefiderocol was non-inferior, but not superior to standard of care empiric treatment of hospital-acquired and healthcare-associated Gram-negative bloodstream infection, in an open-label, multi-national trial¹

The “GAME CHANGER” trial was…